Risk factors

Atara Biotherapeutics (ATRA) risk factors

Item 1A of every Atara Biotherapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open ATRA in Gloomberb →
  • FY2025 10-K risk factors

    80 risks, 8 new, 12 dropped, 22 reworded since the prior year. Severe cash shortage with only $8.5 million remaining as of December 31, 2025, threatening operations. Reliance on single approved product Ebvallo and partner Pierre Fabre for commercialization. Ongoing executive departures and staff reductions straining internal financial controls.

    Filed Mar 16, 2026
  • FY2024 10-K risk factors

    84 risks. The company relies heavily on a single approved product, partnerships, and additional capital to survive ongoing losses and workforce reductions.

    Filed Mar 07, 2025